RT Journal Article
SR Electronic
T1 Telmisartan-induced sprue-like enteropathy: a case report
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP 49
OP 51
DO 10.1136/ejhpharm-2018-001669
VO 27
IS 1
A1 Alzueta, Natalia
A1 Echeverría, Amaya
A1 Sanz, Lorea
A1 Fontela, Carmen
A1 Acín, Teresa
A1 Montenegro, Lidia
A1 Garjón, Javier
YR 2020
UL http://ejhp.bmj.com/content/27/1/49.abstract
AB A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40 mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies.